Ji Yan Biomedical and Taipei Medical University Launch Research Collaboration on MSC/Exosome Applications in Parkinson’s Disease

February 2025 — Taipei

Ji Yan Biomedical today announced the establishment of a targeted research collaboration with Taipei Medical University (TMU) to explore the potential of mesenchymal stem cells (MSCs) in addressing Parkinson’s disease, a leading neurodegenerative disorder worldwide.

This academic-industry partnership will focus on investigating MSC functionality in neurodegeneration models, evaluating their regenerative and immunomodulatory properties, and assessing translational potential for future applications in neurological diseases.

The academic lead for the project is Dr. Tsung-I Hsu, Professor at TMU, whose research expertise spans neuroimmunology, stem cell biology, and translational neuroscience.

This collaboration reflects Ji Yan Biomedical’s broader strategy to integrate cutting-edge cell platforms with academic excellence to address areas of significant unmet medical need.

“We are pleased to work with Taipei Medical University to explore the emerging role of MSCs in neurodegenerative research,” said Dr. Ethan Shen, CEO of Ji Yan Biomedical. “This collaboration reinforces our commitment to advancing innovative science for future healthcare solutions.”

The collaboration is governed by a mutual confidentiality and intellectual property agreement, and all research activities will comply with institutional ethics policies and applicable regulatory standards.

About Ji Yan Biomedical

Ji Yan Biomedical is a biotechnology company pioneering next-generation cell therapies and exosome-based solutions for oncology, regenerative medicine, and immunology. The company engages with leading academic institutions to advance translational research and scientific innovation.